Tyrosine kinase inhibitorFDA-approvedSecond-line
Neratinib
How it works
Blocks the HER2 receptor on cancer cells, preventing growth signals and inhibiting tumor growth.
Cancer types
Breast Cancer— HER2-positive
Efficacy
In clinical trials, around 29% of patients with HER2-positive breast cancer who received neratinib had an objective response, with median progression-free survival of approximately 11 months.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Testing New Anti-cancer Drugs for HER2 Gene Changes | Pancreatic Cancer | phase-1 | — | Source → |
| Testing Niraparib and Neratinib in Advanced Solid Tumors and Ovarian Cancer | Ovarian Cancer | phase-1 | — | Source → |
| Testing a Combination Therapy for ER-Positive, HER-2 Positive Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Neratinib May Help Reduce Vascular Inflammation and Atherosclerosis | Breast Cancer | animal-study | Treatment with neratinib decreased the plaque burden, reduced the necrotic core size, and mitigated lesional macrophage infiltration. | Source → |
| Neratinib Derivative 7A Shows Promise in Treating Colon Cancer | Colorectal Cancer | lab-study | — | Source → |
| Neratinib Use in Early-Stage Breast Cancer Patients | Breast Cancer | observational | — | Source → |
| Neratinib Reduces Breast Cancer Recurrence in Some Patients | Breast Cancer | phase-3 | Neratinib reduces the risk of recurrence and significantly improves invasive disease-free survival of patients with early-stage HER2+ breast cancer. | Source → |
| Calcitriol Shows Promise in Treating ErbB2-positive Breast Cancer | Breast Cancer | lab-study | Calcitriol significantly reduced the viability of SK-BR-3 cells, similar to neratinib. | Source → |
| Neratinib Safety in Older Adults with HER2 Amplified Breast Cancer | Breast Cancer | phase-2 | Median progression free survival was 2.6 months, and median overall survival was 17.4 months. | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.